Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck reports data for Erbitux vs. Avastin in colorectal cancer

Merck KGaA (Xetra:MRK) said first-line treatment with Erbitux cetuximab plus FOLFIRI chemotherapy missed the primary endpoint of significantly

Read the full 187 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE